Cover Image
Market Research Report
Product code 
1058093

Acromegaly - Epidemiology Forecast - 2032

Published: Pre-Order | DelveInsight Business Research LLP | 75 Pages | Delivery time: 2-10 business days

Price

Back to Top
Acromegaly - Epidemiology Forecast - 2032
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 75 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

DelveInsight's "Acromegaly- Epidemiology Forecast-2032" report delivers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Acromegaly Understanding

The DelveInsight's Acromegaly epidemiology report gives a thorough understanding of Acromegaly by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones and releases them into the bloodstream as needed by the body. These hormones regulate many different bodily functions. In most patients, acromegaly is caused by the growth of a benign tumor (adenoma) arising from the pituitary gland. Symptoms of acromegaly include abnormal enlargement in bones of the hands, arms, feet, legs, and head. Enlargement of the bones in the jaws and the front of the skull are typically the most apparent bony changes.

Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients are not able to put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth.

Diagnosis

Screening is recommended for all patients presenting with clinical features of acromegaly (such as mass tumor effects, systemic effects of GH/IGF-1 excess, cardiovascular and metabolic features, respiratory and bone/joint manifestations, and/or other endocrine consequences). However, screening may also be considered in patients with several medical conditions associated with acromegaly, such as type 2 diabetes mellitus, carpal tunnel syndrome, debilitating arthritis, hypertension, and sleep apnea. Biochemical screening is the first step for an acromegaly diagnosis. Endocrine Society guidelines and experts' consensus recommend using age- and sex-adjusted IGF-1 levels in combination with GH nadir during an oral glucose tolerance test (OGTT) to diagnose and rule out acromegaly. Measuring serum IGF-1 is usually the initial screening test.

Levels of GH in the blood can change throughout the day. A reliable way to track GH in the body is by measuring the level of IGF-I in the blood. In most cases, a high IGF-I level suggests that a person has acromegaly. An oral glucose tolerance test to confirm the diagnosis. For this test, the patient will drink a sugary liquid. A health professional will then test the blood every half hour for 2 h to measure growth hormone levels. The sugar in the drink will normally cause GH levels to fall. But if the body is making too much of the hormone, these levels will not go down enough-thereby confirming the diagnosis of acromegaly. If the blood tests confirm that the body is making too much GH, the doctor will conduct imaging tests to locate and measure the tumor that may be causing the problem.

Acromegaly Epidemiology

The Acromegaly epidemiology section provides insights about historical and current Acromegaly patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acromegaly epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

In the year 2021, the total diagnosed prevalent cases of Acromegaly was 57,824 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032 segmented by seven major markets.

The disease epidemiology covered in the report provides historical as well as forecasted Acromegaly epidemiology [segmented as Total Diagnosed prevalent Cases of Acromegaly, Total Tumor origin-specific Cases of Acromegaly, Total Gender-specific Cases of Acromegaly, Total Tumor size Cases of Acromegaly, Total Treated Cases of Acromegaly] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Acromegaly Epidemiology

The epidemiology segment also provides the Acromegaly epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL Views:

To keep up with the current Acromegaly patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Acromegaly domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report:

  • The report covers the descriptive overview of Acromegaly, explaining its causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Acromegaly.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by diagnosed prevalent cases of Acromegaly, total Tumor origin-specific cases of Acromegaly, total Gender-specific cases of Acromegaly, total Tumor size cases of Acromegaly, and total treated cases of Acromegaly.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acromegaly
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Acromegaly Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Acromegaly Epidemiology Segmentation

Key Questions

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of Acromegaly?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Acromegaly patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acromegaly in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about Acromegaly?
  • Out of all 7MM countries, which country would have the highest prevalent population of Acromegaly during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Acromegaly Disease market
  • To understand the future market competition in the Acromegaly Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acromegaly Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Acromegaly Disease market
  • To understand the future market competition in the Acromegaly Disease market
Product Code: DIEI0017

Table of Contents

1. Key Insights

2. Report Introduction

3. Acromegaly Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Acromegaly in 2019
  • 3.2. Market Share (%) Distribution of Acromegaly in 2032

4. Executive Summary of Acromegaly

  • 4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Causes for Acromegaly
  • 6.3. Risk factors of acromegaly
  • 6.4. Signs and symptoms of Acromegaly
  • 6.5. Biomarkers of Acromegaly
  • 6.6. Clinical Manifestations of Acromegaly
    • 6.6.1. Osteoarticular Manifestations
    • 6.6.2. Cardiovascular Manifestations
    • 6.6.3. Respiratory Manifestations
    • 6.6.4. Endocrinological and Other Manifestations
    • 6.6.5. Gastrointestinal Manifestations
  • 6.7. Genetic background for acromegaly
    • 6.7.1. Familial isolated pituitary adenoma
    • 6.7.2. AIP (Aryl Hydrocarbon Receptor Interacting Protein)
    • 6.7.3. Multiple endocrine neoplasia types 1 and 4 (MEN1 and MEN4)
    • 6.7.4. Carney complex
    • 6.7.5. McCune-Albright syndrome
    • 6.7.6. GH excess in neurofibromatosis type 1
    • 6.7.7. Somatic changes in somatotropinomas
  • 6.8. Pathophysiology of Acromegaly
  • 6.9. Complications
    • 6.9.1. Bone Complications from Acromegaly
    • 6.9.2. Soft Tissue Complications from Acromegaly
    • 6.9.3. Pituitary Hormone Deficiencies
    • 6.9.4. Sleep Apnea
    • 6.9.5. Heart Problems
    • 6.9.6. Diabetes
    • 6.9.7. Colon Polyps

7. Screening and Diagnosis

  • 7.1. Diagnostic Algorithm
  • 7.2. Blood tests
    • 7.2.1. IGF test
    • 7.2.2. Oral glucose tolerance test
  • 7.3. Imaging tests
    • 7.3.1. Magnetic resonance imaging
    • 7.3.2. Computed tomography scan
  • 7.4. Differential Diagnosis

8. Treatment

  • 8.1. Treatment Algorithm
  • 8.2. Surgical Therapy
    • 8.2.1. Surgical Techniques
  • 8.3. Medical Agents
  • 8.4. Radiotherapy
  • 8.5. Management of Acromegaly in Pregnancy

9. Diagnosis and Treatment Guidelines

  • 9.1. Pituitary Society Acromegaly Management Guidelines
  • 9.2. An Endocrine Society Clinical Practice Guideline 2014
  • 9.3. American Association of Clinical Endocrinologists Medical Guidelines (AACE)

10. Conclusion

11. Epidemiology and Patient Population

  • 11.1. Key Findings
  • 11.2. Epidemiology of Acromegaly
  • 11.3. Epidemiology Scenario
    • 11.3.1. Total Diagnosed prevalent Cases of Acromegaly
    • 11.3.2. Total Tumor origin-specific Cases of Acromegaly
    • 11.3.3. Total Gender-specific Cases of Acromegaly
    • 11.3.4. Total Tumor size Cases of Acromegaly
    • 11.3.5. Total Treated Cases of Acromegaly

12. Unmet Needs

13. Appendix

  • 13.1. Bibliography
  • 13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

  • Table 1: Summary of Acromegaly, Market, Epidemiology, and Key Events (2019-2032)
  • Table 2: Total Diagnosed prevalent Cases of Acromegaly (2019-2032)
  • Table 3: Total Tumor origin-specific Cases of Acromegaly (2019-2032)
  • Table 4: Total Gender-specific Cases of Acromegaly (2019-2032)
  • Table 5: Total Tumor size Cases of Acromegaly (2019-2032)
  • Table 6: Total Treated Cases of Acromegaly (2019-2032)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Understanding of Acromegaly
  • Figure 3: Comorbidities of Acromegaly
  • Figure 4: Sign and Symptoms of Acromegaly
  • Figure 5: Clinical Manifestations of Acromegaly
  • Figure 6: Genetic background for Acromegaly
  • Figure 7: Pathophysiology of Acromegaly
  • Figure 8: Complications for Acromegaly
  • Figure 9: Diagnostic Algorithm for Acromegaly
  • Figure 10: Treatment Algorithm for Acromegaly
  • Figure 11: Total Diagnosed prevalent Cases of Acromegaly in the 7MM (2019-2032)
  • Figure 12: Total Tumor origin-specific Cases of Acromegaly in the 7MM (2019-2032)
  • Figure 13: Total Gender-specific Cases of Acromegaly in the 7MM (2019-2032)
  • Figure 14: Total Tumor size Cases of Acromegaly in the 7MM (2019-2032)
  • Figure 15: Total Treated Cases of Acromegaly in the 7MM (2019-2032)